Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 450 days CR can increase as high as 47%

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon Jun 11, 2023 9:39am

204 Views

Post# 35490486

RE:450 days CR can increase as high as 47%

Nice spreadsheet RH! Very slick.

I would argue that using 80% CR rate for the 5 pending at 90 days may be a bit on the more optimistic side. I would use 65% but that is just me errring on the conservative side.

When I did a similar spreadsheet I got the same kind of predictions overall so lines up nicely.

Now if we knew something about the malignancy type, number of tumours on the wall of the bladder, etc, we might know more about the probability of certain outcomes in a more granular way.

That would be nice.

DJ

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia